Comparable performance indicators for breast cancer screening in the European Union (EU) have not been previously reported. We estimated adjusted breast cancer screening positivity rate (PR) and detection rates (DR) to investigate variation across EU countries. For the age 50–69 years, the adjusted EU‐pooled PR for initial screening was 8.9% (cross‐programme variation range 3.2–19.5%) while DR of invasive cancers was 5.3/1,000 (range 3.8–7.4/1,000) and DR of ductal carcinoma in situ (DCIS) was 1.3/1,000 (range 0.7–2.7/1,000). For subsequent screening, the adjusted EU‐pooled PR was 3.6% (range 1.4–8.4%), the DR was 4.0/1,000 (range 2.2–5.8/1,000) and 0.8/1,000 (range 0.5–1.3/1,000) for invasive and DCIS, respectively. Adjusted performance indicators showed remarkable heterogeneity, likely due to different background breast cancer risk and awareness between target populations, and also different screening protocols and organisation. Periodic reporting of the screening indicators permits comparison and evaluation of the screening activities between and within countries aiming to improve the quality and the outcomes of screening programmes. Cancer Screening Registries would be a milestone in this direction and EU Screening Reports provide a fundamental contribution to building them.

中文翻译：

---

欧盟乳腺癌筛查的绩效指标：各国筛查阳性率和检出率的比较。


此前尚未报道过欧盟 (EU) 乳腺癌筛查的可比绩效指标。我们估计了调整后的乳腺癌筛查阳性率 (PR) 和检出率 (DR)，以调查欧盟国家之间的差异。对于 50-69 岁的人群，初始筛查的调整后欧盟汇总 PR 为 8.9%（跨项目变异范围为 3.2-19.5%），而浸润性癌症的 DR 为 5.3/1,000（范围为 3.8-7.4/1,000），DR 为导管原位癌(DCIS) 的发生率为 1.3/1,000（范围 0.7–2.7/1,000）。对于后续筛查，调整后的欧盟汇总 PR 为 3.6%（范围 1.4-8.4%），侵入性和非特异性筛查的 DR 为 4.0/1,000（范围 2.2-5.8/1,000）和 0.8/1,000（范围 0.5-1.3/1,000）。分别是DCIS。调整后的绩效指标显示出显着的异质性，这可能是由于目标人群之间不同的乳腺癌风险背景和意识，以及不同的筛查方案和组织。定期报告筛查指标可以对国家之间和国家内部的筛查活动进行比较和评估，旨在提高筛查计划的质量和结果。癌症筛查登记处将成为这一方向的里程碑，欧盟筛查报告为建立癌症筛查登记处做出了根本性贡献。